Nucleotide Synthesis Pathways and De Novo Biosynthesis
Nucleotide synthesis occurs through two primary pathways: de novo synthesis and salvage pathways. Each route serves different cellular needs and uses different starting materials.
De Novo Biosynthesis Process
De novo biosynthesis constructs nucleotide bases from simple precursors like ribose-5-phosphate, glutamine, and aspartate. Pyrimidine synthesis occurs in the cytoplasm and produces the base first. It then attaches to the ribose sugar.
Purines follow a different route. They build directly on the ribose sugar through a 10-step process. This constructs the imidazole ring attached to the phosphorylated sugar.
Key Enzymes and Regulation
The first committed enzyme in pyrimidine synthesis is carbamoyl phosphate synthetase II (CPS II). This catalyzes the formation of carbamoyl phosphate, which combines with aspartate to begin the cycle.
The first committed enzyme in purine synthesis is phosphoribosyl pyrophosphate (PRPP) synthetase. This enzyme activates ribose-5-phosphate.
Both pathways require multiple cofactors: ATP, GTP, and various B vitamins. End products like dTTP, dGTP, and dATP provide negative feedback through allosteric inhibition.
Salvage Pathways
Salvage pathways provide a more economical route when cells have adequate substrate availability. Key enzymes include:
- Adenine phosphoribosyltransferase (APRT): recycles adenine bases
- Hypoxanthine-guanine phosphoribosyltransferase (HGPRT): recycles hypoxanthine and guanine
Mutations in salvage pathway enzymes cause diseases like Lesch-Nyhan syndrome. Understanding the distinction between de novo and salvage pathways helps explain how cells regulate nucleotide pools and develop metabolic diseases.
DNA Replication and the DNA Polymerase Complex
DNA replication is a highly coordinated process that duplicates genetic material with remarkable accuracy. This semiconservative process ensures each new DNA molecule contains one original strand and one newly synthesized strand.
The DNA Polymerase and Core Process
DNA polymerase III in prokaryotes catalyzes nucleotide addition in the 5' to 3' direction. Eukaryotes use DNA polymerase alpha, delta, and epsilon instead.
DNA polymerase requires a primer with a 3'-OH group. Primase, an RNA polymerase, synthesizes short RNA primers to start synthesis. The replication fork moves at approximately 1000 nucleotides per second in bacteria and 50 nucleotides per second in eukaryotes.
The Leading and Lagging Strand Problem
The lagging strand presents a fundamental challenge. It must synthesize discontinuously as Okazaki fragments. These are 1000-2000 nucleotides in prokaryotes or 100-200 nucleotides in eukaryotes.
This occurs because DNA polymerase only adds nucleotides in the 5' to 3' direction. One template strand runs 3' to 5', requiring fragmented synthesis.
Accessory Proteins and Proofreading
Several accessory proteins ensure efficient replication:
- Helicase: unwinds the double helix
- Single-strand binding proteins (SSB proteins): prevent re-annealing
- Topoisomerases: relieve tension from unwinding
- Ligase: seals gaps between Okazaki fragments
DNA polymerase III possesses 3' to 5' exonuclease activity for proofreading. This increases fidelity to approximately one error per 10^7 nucleotides.
Regulation of replication initiation involves licensing factors in eukaryotes and DnaA proteins in prokaryotes. These ensure DNA replicates exactly once per cell cycle.
Transcription, RNA Processing, and Gene Expression
Transcription is the process by which RNA polymerase synthesizes mRNA, tRNA, and rRNA from a DNA template. Prokaryotic and eukaryotic transcription differ significantly in complexity and regulation.
Prokaryotic vs. Eukaryotic Transcription
In prokaryotes, RNA polymerase recognizes promoter sequences like the -10 box (Pribnow box) and -35 box. These appear upstream of the transcription start site.
In eukaryotes, the process is more complex. RNA polymerase II synthesizes mRNA and works with numerous transcription factors. Key promoter elements include the TATA box and CAAT box.
The Transcription Process
RNA polymerase catalyzes formation of phosphodiester bonds between ribonucleotides in the 5' to 3' direction. The DNA template strand guides this synthesis.
Initiation requires sigma factors in prokaryotes or general transcription factors (TFIID, TFIIB, TFIIE) in eukaryotes. Elongation continues until the polymerase encounters a termination signal.
Prokaryotic Termination and Eukaryotic Processing
Prokaryotic termination involves rho-dependent or rho-independent mechanisms. Eukaryotic RNA polymerase II transcribes past the polyadenylation signal. Cleavage occurs post-transcriptionally.
Eukaryotic mRNA Processing
Eukaryotic mRNA undergoes extensive modifications:
- 5' capping: adds 7-methylguanosine to the start
- 3' polyadenylation: adds approximately 200 adenine nucleotides
- Splicing: removes introns and joins exons
The spliceosome performs splicing. It consists of small nuclear RNAs (snRNAs) and proteins.
Alternative splicing increases protein diversity. It allows different combinations of exons to join together. These modifications increase mRNA stability, facilitate nucleus export, and enhance translation efficiency.
Nucleotide Catabolism and Purine Degradation Pathways
Nucleotide catabolism breaks down nucleotides into constituent parts for recycling or complete degradation. The pathways differ significantly between purines and pyrimidines.
Purine Degradation to Uric Acid
Purine degradation proceeds through a well-defined pathway. The end product in humans is uric acid, which is excreted through urine.
Adenine undergoes deamination by adenosine deaminase to form inosine. Adenosine can also deaminate directly to inosine.
Inosine is phosphorylated to inosinate, which deaminates by inosinate dehydrogenase to form xanthylate. This oxidizes to urate by xanthine oxidase.
Guanine deaminates directly by guanine deaminase to xanthine, which oxidizes to urate by xanthine oxidase.
Clinical Significance of Xanthine Oxidase
Xanthine oxidase is important because it produces reactive oxygen species as a byproduct. Its inhibitor allopurinol treats gout and hyperuricemia by preventing urate formation.
Adenosine deaminase deficiency causes accumulated adenosine and deoxyadenosine. This leads to toxic deoxynucleotide accumulation in lymphocytes, resulting in severe combined immunodeficiency (SCID).
Pyrimidine Catabolism
Pyrimidine catabolism differs significantly from purine catabolism. Cytosine deaminase converts cytosine to uracil.
The pyrimidine ring then cleaves to produce beta-alanine and ammonia. This converts further to beta-alanine and CO2.
Uracil from RNA or from cytidine and uridine degradation undergoes the same cleavage process. Understanding these pathways explains metabolic diseases and informs drug development, as many chemotherapy drugs target nucleotide metabolism.
Regulation of Nucleic Acid Metabolism and Allosteric Control
Regulation of nucleic acid synthesis is critical for maintaining appropriate nucleotide pools. Cells must prevent excessive production and resource waste while supporting DNA and RNA synthesis.
Pyrimidine Synthesis Regulation
Pyrimidine synthesis is primarily controlled through allosteric regulation. Carbamoyl phosphate synthetase II is the first committed enzyme.
This enzyme is inhibited by end products UTP and CTP. It is activated by ATP and PRPP. This creates negative feedback preventing overproduction of pyrimidines.
Dihydroorotate dehydrogenase is also regulated by the nucleotide pool. These regulatory points prevent wasteful synthesis.
Purine Synthesis Regulation
Phosphoribosyl pyrophosphate amidotransferase is the first committed enzyme in purine synthesis. It is inhibited by end products: AMP, GMP, IMP, ADP, and GDP.
This prevents accumulation of purines when nucleotide pools are adequate. The balance between purine and pyrimidine synthesis is maintained through competing use of PRPP as a substrate.
The PRPP Competition System
When one pathway is active, it consumes PRPP and reduces availability for the other pathway. This elegant system prevents one pathway from dominating at the expense of the other.
Deoxyribonucleotide Reduction Control
Ribonucleotide reductase catalyzes the reduction of ribonucleotides to deoxyribonucleotides for DNA synthesis. This enzyme uses complex allosteric regulation.
ATP binding at the general activity site activates the enzyme. dATP binding causes allosteric inhibition, preventing excess deoxyribonucleotide production.
The enzyme's specificity site also responds to allosteric control:
- ATP or dATP binding: favors CDP reduction
- dGTP or dTTP binding: shifts specificity toward other substrates
These regulatory mechanisms ensure balanced nucleotide pools. They ensure deoxyribonucleotides match DNA synthesis needs. They prevent wasteful overproduction when nucleotide pools are adequate.
